Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target

Stock Track

04/01

3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.

CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.

While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1147015943"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147015943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147015943?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147015943","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target","media":"Stock Track","content":"<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"","article_id":"1147015943","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147015943","pubTimestamp":1775024973,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股轨迹|三生制药盘中大涨11.66%中金维持跑赢大盘评级目标61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}